NEJM shared a post on X:
“In papillary kidney cancer, particularly hereditary leiomyomatosis–associated cases, bevacizumab plus erlotinib showed strong antitumor activity.
The likelihood of a response was higher in hereditary cases than in sporadic ones.
Full study results.”
Title: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
Authors: Ramaprasad Srinivasan, Sandeep Gurram, Eric A. Singer, Abhinav Sidana, Munjid Al Harthy, Mark W. Ball, Julia C. Friend, Lisa Mac, Erin Purcell, Cathy D. Vocke, Christopher J. Ricketts, Heidi H. Kong, Edward W. Cowen, Ashkan A. Malayeri, Joanna H. Shih, Maria J. Merino, W. Marston Linehan
You can read the Full Article on The New England Journal of Medicine
Francesco Massari, Associate Professor at University of Bologna and Medical Oncologist focused on Genitourinary Cancer at The University Hospital of Bologna IRCCS, shared this post, adding:
“An important trial for a rare RCC.
Another good news for our patients.”
More posts featuring NEJM.
